Loading...
ATXS logo

Astria Therapeutics, Inc.NasdaqGM:ATXS 주식 보고서

시가총액 US$718.1m
주가
US$12.58
US$13
3.2% 저평가 내재 할인율
1Y68.0%
7D1.1%
1D
포트폴리오 가치
​
보기

Astria Therapeutics, Inc.

NasdaqGM:ATXS 주식 리포트

시가총액: US$718.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Astria Therapeutics (ATXS) 주식 개요

아스트리아 테라퓨틱스는 미국에서 알레르기 및 면역 질환 치료제의 발견, 개발 및 상용화에 종사하는 바이오 제약 회사입니다. 자세히 보기

ATXS 펀더멘털 분석
스노우플레이크 점수
가치 평가3/6
미래 성장2/6
과거 실적0/6
재무 건전성6/6
배당0/6

강점

공정 가치 추정치보다 낮은 84.1% 에서 거래

수익은 연간 57.5% 증가할 것으로 예상됩니다.

위험 분석

수익이 USD$1m 미만입니다($706K)

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.


ATXS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Astria Therapeutics, Inc. 경쟁사

가격 이력 및 성과

Astria Therapeutics 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$12.58
52주 최고가US$13.29
52주 최저가US$3.56
베타0.019
1개월 변동-2.86%
3개월 변동-0.16%
1년 변동67.96%
3년 변동-8.51%
5년 변동-35.88%
IPO 이후 변동-98.39%

최근 뉴스 및 업데이트

Seeking Alpha • Nov 30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Summary I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Nov 30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Summary I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Read the full article on Seeking Alpha
분석 기사 • Jul 08

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Mar 13

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 18

Astria Therapeutics: A High-Conviction Bet On HAE

Summary Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation. Astria's strategic focus on patient-centric dosing regimens and regulatory strength could reshape treatment landscapes, but clinical and commercial execution remains crucial for success. Read the full article on Seeking Alpha
Seeking Alpha • Nov 27

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Summary Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience. Risks are minimal given the promising data, making ATXS stock a buy due to its excellent data, market potential, and upcoming catalysts. Read the full article on Seeking Alpha
분석 기사 • Nov 14

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Astria Therapeutics...
분석 기사 • Jul 11

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 24

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, with plans for a Phase 1a study in 2025. Despite positive early data for STAR-0215, competition in the HAE market is fierce and likely to get more crowded with promising new treatments on the horizon. An updated analysis of Astria Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 04

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Summary Astria Therapeutics (formerly Catabasis Pharmaceuticals) acquired Quellis Biosciences and its lead program, STAR-0215, for the treatment of hereditary angioedema (HAE) in 2021. The company has successfully completed a Phase 1 study for STAR-0215, demonstrating positive results in terms of safety, tolerability, and efficacy. Astria is now moving forward with a Phase 1b/2 study to establish proof-of-concept for STAR-0215 in HAE patients, with initial results expected in Q1 2024. The promise of HAE data in Q124 appears to have lifted the share price and allowed the company to raise funds. If the promise of upcoming is already baked into the share price, given how far behind the competition Astria is in HAE, and in atopic dermatitis with a second candidate, I would give its stock a "sell" rating. Read the full article on Seeking Alpha
분석 기사 • Dec 10

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Jul 27

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Astria Therapeutics...
분석 기사 • Apr 03

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Nov 30

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Aug 01

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jul 15

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS) names more than 20 years of clinical development experience in rare diseases and other indications Chris Morabito, M.D., as Chief Medical Officer.  Dr. Morabito most recently served as the Chief Medical Officer at Fulcrum Therapeutics.
Seeking Alpha • Jun 30

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences. The acquisition brought QLS-215, a preclinical stage monoclonal antibody with a potentially improved profile compared to prophylactic market leader Takhzyro. Much longer half-life and increased potency could result in less frequent administration and it could also improve efficacy. The HAE market is increasingly competitive with additional promising therapies in development, but if preclinical data of QLS-215 translate well into humans, Catabasis could deliver significant gains in the following years.

주주 수익률

ATXSUS BiotechsUS 시장
7D1.1%1.3%1.8%
1Y68.0%33.0%28.4%

수익률 대 산업: ATXS은 지난 1년 동안 33%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: ATXS은 지난 1년 동안 28.4%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is ATXS's price volatile compared to industry and market?
ATXS volatility
ATXS Average Weekly Movement2.7%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

안정적인 주가: ATXS는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: ATXS의 주간 변동성은 지난 1년간 10%에서 3%로 감소했습니다.

회사 소개

설립직원 수CEO웹사이트
200878Jill Milnewww.astriatx.com

아스트리아 테라퓨틱스는 미국에서 알레르기 및 면역 질환 치료제의 발견, 개발 및 상용화에 종사하는 바이오 제약 회사입니다. 주요 제품 후보로는 유전성 혈관부종 치료를 위한 임상 1b/2상 시험 중인 혈장 칼리크라인 단일클론 항체 억제제인 나베니바트가 있습니다. 또한 피부 장벽 기능 상실 및 가려움증과 관련된 면역 질환인 아토피 피부염 치료를 위해 임상 개발 중인 단일 클론 항체 OX40 길항제인 STAR-0310도 개발 중입니다.

Astria Therapeutics, Inc. 기초 지표 요약

Astria Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
ATXS 기초 통계
시가총액US$718.13m
순이익 (TTM)-US$124.03m
매출 (TTM)US$706.00k
1,017x
주가매출비율(P/S)
-5.8x
주가수익비율(P/E)

ATXS는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
ATXS 손익계산서 (TTM)
매출US$706.00k
매출원가US$0
총이익US$706.00k
기타 비용US$124.74m
순이익-US$124.03m

최근 보고된 실적

Sep 30, 2025

다음 실적 발표일

해당 없음

주당순이익(EPS)-2.17
총이익률100.00%
순이익률-17,567.99%
부채/자본 비율0%

ATXS의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/01/27 16:50
종가2026/01/22 00:00
수익2025/09/30
연간 수익2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Astria Therapeutics, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Jonathan WollebenCitizens JMP Securities, LLC